MAPT and Alzheimer disease: Compound 21 had potent in vitro GSK‐3β inhibitory activity with favorable in vitro pharmacokinetic profiles, showing a significant tau phosphorylation reduction and excellent pharmacokinetic profiles in AD mice after oral administration.87